Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Ixazomib is the first investigational oral proteasome inhibitor to be studied clinically. In this phase 1 trial, 60 patients with relapsed/refractory multiple myeloma (median of 4 prior lines of therapy; bortezomib, lenalidomide, thalidomide, and carfilzomib/marizomib in 88%, 88%, 62%, and 5%, respe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Richardson, Paul G., Baz, Rachid, Wang, Michael, Jakubowiak, Andrzej J., Laubach, Jacob P., Harvey, R. Donald, Talpaz, Moshe, Berg, Deborah, Liu, Guohui, Yu, Jiang, Gupta, Neeraj, Di Bacco, Alessandra, Hui, Ai-Min, Lonial, Sagar
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2014
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4574453/
https://ncbi.nlm.nih.gov/pubmed/24920586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-01-548826
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky